A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Amubarvimab/romlusevimab-Brii-Biosciences (Primary) ; Bamlanivimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Ensovibep (Primary) ; Sotrovimab (Primary) ; Remdesivir
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms ACTIV-3; TICO

09 Nov 2023 Results (n=2149) published in the Journal of Infectious Diseases
23 Aug 2023 Status changed from active, no longer recruiting to completed.
18 Aug 2023 This trial has been completed in Denmark (Date of the global end of the trial: 14-Jul-2023), according to the European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com